Clinical Trials Directory

The study has three parts called Screening, Treatment, and Follow up. Most people will be in the study for about 21 months, but the time may be shorter or longer. People are placed into groups by chance. Two people out of every three will get two medicines called casdatifan and cabozantinib. One person out of every three will get cabozantinib and a pill with no medicine. No one will know which group they are in. All medicines are taken by mouth once each day at home, and people write down each dose in a study diary. During the study, people will have regular blood tests, heart checks, and mouth exams. They will also have CT or MRI scans about every eight weeks for two years, then every twelve weeks. People will answer questionnaires about once a month. The study uses casdatifan, which is a new medicine being tested, and cabozantinib, which is already approved to treat this type of kidney cancer.

If you choose to join this study, you or your child, will:

• Allow us access to your medical record for up to 5 years
• Answer questions about your health history and current symptoms
• Have a nasal swab
• Give a stool sample
• Complete 3 follow-up phone calls
• Have blood drawn (only if in the hospital or l)

We are doing this study to find out if pelvic floor physical therapy can improve sexual function for women who have undergone pelvic radiation.

We are doing this study to evaluate an experimental vaccine that is being developed to protect against C. diff infections. We want to find out if the study vaccine is effective for people who are at an increased risk for C. diff. We will look at how well the study vaccine can prevent infections and/or lower the severity of infections.